Strategies for inhibition of MDR1 gene expression

Molecular Pharmacology

Volumn 66, Issue 2, 2004, Pages 268-275

  Xu, Dong ^a   Kang, Hyunmin ^a   Fisher, Michael ^a   Juliano, Rudy L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE PROTEIN; DOUBLE STRANDED RNA; DOXORUBICIN; GLYCOPROTEIN P; MEMBRANE PROTEIN; RHODAMINE 123; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; WESTERN BLOTTING;

DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION; GENES, MDR; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 3342949987     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.2.268     Document Type: Article

References (31)

1. Alahari SK, Dean NM, Fisher MH, Delong R, Manoharan M, Tivel KL, and Juliano RL (1996) Inhibition of expression of the multidrug resistance- associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 50:808-819.
2. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, and Juliano RL (1998) Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther 286:419-428.
3. Alahari SK, Lee JW, and Juliano RL (2000) Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol 151:1141-1154.
4. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
5. Beerli RR and Barbas CF 3rd (2002) Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol 20:135-141.
6. Bennett CF (1998) Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharmacol 55:9-19.
7. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47:943-946.
8. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, and Bonnet JD (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A South-west Oncology Group study. Cancer 75:815-820.
9. Denhardt DT (1992) Mechanism of action of antisense RNA. Sometime inhibition of transcription, processing, transport, or translation. Ann NYAcad Sci 660:70-76.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411:494-498.
11. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, and Tuschl T (2001b) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO (Eur Mol Biol Organ) J 20:6877-6888.
12. Falke D and Juliano RL (2003) Selective gene regulation with designed transcription factors: implications for therapy. Curr Opin Mol Ther 5:161-166.
13. Fisher AA, Ye D, Sergueev DS, Fisher MH, Shaw BR, and Juliano RL (2002) Evaluating the specificity of antisense oligonucleotide conjugates: a DNA array analysis. J Biol Chem 277:22980-22984.
14. Freelove AC and Zheng R (2002) The power of ribozyme technologies: the logical way ahead for molecular medicine and gene therapy? Curr Opin Mol Ther 4:419-422.
15. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
16. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, and Tuschl T (2003) Sequence, chemistry, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105.
17. Kobayashi H, Dorai T, Holland JF, and Ohnuma T (1994) Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 54:1271-1275.
18. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, and Rossi J (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20:500-505.
19. Leyland-Jones B, Dalton W, Fisher GA, and Sikic BI (1993) Reversal of multidrug resistance to cancer chemotherapy. Cancer 72:3484-3488.
20. McManus MT and Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3:737-747.
21. Nagata J, Kijima H, Hatanaka H, Asai S, Miyachi H, Abe Y, Yamazaki H, Nakamura M, Watanabe N, Mine T, et al. (2002) Reversal of drug resistance using hammer-head ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int J Oncol 21:1021-1026.
22. Nieth C, Priebsch A, Stege A, and Lage H (2003) Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 545: 144-150.
23. Paul CP, Good PD, Winer I, and Engelke DR (2002) Effective expression of small interfering RNA in human cells. Nat Biotechnol 20:505-508.
24. Ramachandran C and Wellham LL (2003) Effect of MDR1 phosphorothioate anti-sense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res 23:2681-2690.
25. Richert ND, Aldwin L, Nitecki D, Gottesman MM, and Pastan I (1988) Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27:7607-7613.
26. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496-7511.
27. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, and Forrester WC (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99:5515-5520.
28. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, and Baker BF (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. JBiol Chem 278:7108-7118.
29. Wu H, Hait WN, and Yang JM (2003) Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63:1515-1519.
30. Xu D, Ye D, Fisher M, and Juliano RL (2002) Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther 302:963-971.
31. Yang CP, Shen HJ, and Horwitz SB (1994) Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86:723-725.